At the beginning of April, Gemini Genomics (Cambridge, UK) entered SNP-centered collaborations with both CuraGen (New Haven, CT) and Sequenom (San Diego, CA, and Hamburg, Germany). Although the deals are separate, they bring CuraGen's extensive database of cSNPs and Sequenom's rapid mass spectroscopy-based resequencing technology together with Gemini's extensive knowledge base in the association of genetic and clinical traits. The aim of the CuraGen–Gemini collaboration is to provide population genetics-based validation for some of the 500,000 single-base variations in human genes that CuraGen has documented. In parallel, Sequenom will check the validity of 240,000 public domain SNPs using, among other resources, DNA samples and clinical information gathered by Gemini from its various populations. Gemini's early work was in twins and disease-associated gene discovery, but—through its acquisition of Eurona Medical (Uppsala, Sweden) and the establishment of Newfound Genomics in Newfoundland (Nat. Biotechnol. 18, 366, 2000)—it is now also working in drug trial populations and founder groups. Paul Kelly, Gemini's CEO, points out that the latest arrangements are part of a broader set of technology collaborations. All of the deals are on a nonexclusive and relatively short-term basis, something that Kelly believes is important in allowing genomics enterprises to remain at the cutting edge.